Pharmacological and genomic profiling identifies NF-κB–targeted treatment strategies for mantle cell lymphoma
Nature Medicine2013Vol. 20(1), pp. 87–92
Citations Over TimeTop 1% of 2013 papers
Rami Rahal, Mareike Frick, Rodrigo Romero, Joshua M. Korn, Robert Kridel, Fong Chun Chan, Barbara Meissner, Hyo-Eun Carrie Bhang, Dave Ruddy, Audrey Kauffmann, Ali Farsidjani, Adnan Derti, Daniel P. Rakiec, Tara L. Naylor, Estelle Pfister, Steve G. Kovats, Sunkyu Kim, Kerstin Dietze, Bernd Dörken, Christian Steidl, Alexandar Tzankov, Michael Hummel, John E. Monahan, Michael Morrissey, Christine Fritsch, William R. Sellers, Vesselina G. Cooke, Randy D. Gascoyne, Georg Lenz, Frank Stegmeier
Related Papers
- → Targets for Ibrutinib Beyond B Cell Malignancies(2015)127 cited
- → Ibrutinib for B cell malignancies(2014)76 cited
- → Highly Potent BTK Degradation Induced By NRX0492 As a Therapeutic Strategy for CLL(2019)3 cited
- → Global Inhibition of Bruton's Tyrosine Kinase (BTK) Delays the Development and Expansion of Chronic Lymphocytic Leukemia (CLL) in the TCL1 Mouse Model of Disease(2012)3 cited
- → Abstract 3761: HSK26784: An oral PROTAC-BTK degrader for multiple B lymphocyte derived malignancies(2020)